Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
469 A phase 1 first in human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.